Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating DNA, Circulating RNA, Circulating Tumor Cells

Mike Makrigiorgos's Biography



Mike Makrigiorgos, Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School

Dr. Makrigiorgos is a Professor of Radiation Oncology and Director of the Medical Physics & Biophysics division at Dana Farber Cancer Institute and Brigham and Women’s Hospitals, Harvard Medical School. He also directs his DNA technology laboratory and the radiation pre-clinical facility. His research interests include the development of novel DNA technologies for molecular diagnostics in Oncology and the identification of circulating cancer biomarkers. Dr. Makrigiorgos is the inventor of several PCR-based techniques for molecular diagnostics, including Balanced-PCR, NaME-PrO technology and COLD-PCR. He is a Member of the Editorial Board of Clinical Chemistry and has published over 150 articles, reviews and book chapters. He received his undergraduate degree in Physics from the University of Athens, Greece, his PhD in Medical Physics from the University of Leeds, UK and his postdoctoral training in radiation biology from Harvard Medical School, Boston.

Mike  Makrigiorgos Image

Enrichment of Mutations in Cancer Gene Panels from Tumors and Circulating DNA, using COLD-PCR

Tuesday, 24 March 2015 at 16:30

Add to Calendar ▼2015-03-24 16:30:002015-03-24 17:30:00Europe/LondonEnrichment of Mutations in Cancer Gene Panels from Tumors and Circulating DNA, using COLD-PCRSELECTBIOenquiries@selectbiosciences.com

Targeted re-sequencing of mutations in cancer-relevant genes provides opportunities for fine-tuning cancer therapy and follow-up during treatment, by examining mutations in tumors and bio-fluids such as circulating DNA from plasma.  However, a major technical limitation has been the lack of sensitivity of cancer re-sequencing panels for mutations below 1-2% abundance, which is frequently the case for circulating DNA. We present a newly developed method via which mutations in numerous amplicons are first enriched via COLD-PCR in a singe-tube reaction, prior to targeted re-sequencing. Using this approach, mutations of 0.01-0.1% abundance can be detected via next generation sequencing.


Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating DNA, Circulating RNA, Circulating Tumor CellsSELECTBIOenquiries@selectbiosciences.com